NeuroDerm is a clinical-stage pharmaceutical company developing next-generation medical care for patients suffering from Parkinson’s disease (PD) and central nervous system (CNS) disorders through the proprietary reformulation of existing drugs that we expect will make a clinically meaningful difference in the quality of patients’ lives.
Product candidates in our portfolio are designed to overcome major deficiencies in current treatments and achieve enhanced clinical efficacy through continuous, controlled administration, primarily subcutaneously or transdermally. Because NeuroDerm’s product candidates are based on patented reformulations of leading, approved drugs, it is believed that most of them qualify for an accelerated, lower risk regulatory pathway to marketing approval.
NeuroDerm has developed a portfolio of product candidates that addresses major unmet needs in the field of Parkinson’s disease and cognition. Specifically in the alleviation of the effects of Parkinson’s disease, the company has four product candidates in different stages of development which offer solution for almost every PD patient – from the moderate to the very severe stage of the disease. To further explore NeuroDerm’s solutions for PD, please see the Product Portfolio.
These developments are backed by a robust intellectual property portfolio that includes several patent families covering the company’s novel formulations.
NeuroDerm has been supported by grants from the Michael J. Fox Foundation for Parkinson’s Research